ZNF259 expression based on
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison Statistical significance Normal-vs-Primary 3.488600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer stage information is not available for 3 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Stage1
9.076600E-01
Normal-vs-Stage2
2.724400E-01
Normal-vs-Stage3
8.226400E-01
Normal-vs-Stage4
6.802400E-04
Stage1-vs-Stage2
9.845700E-02
Stage1-vs-Stage3
8.551200E-01
Stage1-vs-Stage4
3.241400E-03
Stage2-vs-Stage3
1.242230E-01
Stage2-vs-Stage4
2.421300E-03
Stage3-vs-Stage4
6.373700E-02
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient race information is not available for 5 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Caucasian
3.831800E-01
Normal-vs-AfricanAmerican
2.064000E-01
Normal-vs-Asian
1.910000E-01
Caucasian-vs-AfricanAmerican
5.263200E-01
Caucasian-vs-Asian
7.965000E-01
AfricanAmerican-vs-Asian
3.883600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient gender information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Male
3.431000E-01
Normal-vs-Female
3.702800E-01
Male-vs-Female
3.998000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient age information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Age(21-40Yrs)
9.446800E-01
Normal-vs-Age(41-60Yrs)
1.396780E-01
Normal-vs-Age(61-80Yrs)
4.735800E-01
Normal-vs-Age(81-100Yrs)
3.659200E-01
Age(21-40Yrs)-vs-Age(41-60Yrs)
1.265620E-01
Age(21-40Yrs)-vs-Age(61-80Yrs)
4.312400E-01
Age(21-40Yrs)-vs-Age(81-100Yrs)
3.693200E-01
Age(41-60Yrs)-vs-Age(61-80Yrs)
5.918500E-02
Age(41-60Yrs)-vs-Age(81-100Yrs)
5.730200E-01
Age(61-80Yrs)-vs-Age(81-100Yrs)
6.414000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Drinking status is not available for 80 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Non Drinker
5.377400E-01
Normal-vs-Daily Drinker
4.148600E-01
Normal-vs-Weekly Drinker
2.598400E-01
Normal-vs-Occasional Drinker
2.700200E-01
Normal-vs-Social Drinker
4.324600E-01
Non Drinker-vs-Daily Drinker
3.494200E-01
Non Drinker-vs-Weekly Drinker
4.651200E-01
Non Drinker-vs-Occasional Drinker
4.631400E-01
Non Drinker-vs-Social Drinker
8.348400E-01
Daily Drinker-vs-Weekly Drinker
8.348400E-01
Daily Drinker-vs-Occasional Drinker
7.693800E-01
Daily Drinker-vs-Social Drinker
5.415200E-01
Weekly Drinker-vs-Occasional Drinker
9.511600E-01
Weekly Drinker-vs-Social Drinker
6.173000E-01
Occasional Drinker-vs-Social Drinker
6.368600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma
Subtype descriptions Grade 1 Well differentiated (low grade)
Grade 2 Moderately differentiated (intermediate grade) Grade 3 Poorly differentiated (high grade)
Grade 4 Undifferentiated (high grade)
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Grade 1
9.043000E-01
Normal-vs-Grade 2
8.468600E-01
Normal-vs-Grade 3
7.447000E-01
Normal-vs-Grade 4
1.000000E+00
Grade 1-vs-Grade 2
4.46419999999836E-05
Grade 1-vs-Grade 3
1.92030000001342E-06
Grade 1-vs-Grade 4
9.043000E-01
Grade 2-vs-Grade 3
3.216500E-02
Grade 2-vs-Grade 4
8.468600E-01
Grade 3-vs-Grade 4
7.447000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Diabetes status information is not available for 30 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Diabetic
4.528000E-01
Normal-vs-NonDiabetic
3.601000E-01
Diabetic-vs-NonDiabetic
5.240400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Pancreatitis status is not available for 39 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Pancreatitis
2.325600E-02
Normal-vs-NoPancreatitis
3.993800E-01
Pancreatitis-vs-NoPancreatitis
7.668500E-02
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Nodal metastais status is not available for 1 sample and cancer in nearby lymph nodes cannot be measured (NX) in 4 samples.
pathologic_N descriptions N0 No regional lymph node metastasis
N1 Metastases in 1 to 3 axillary lymph nodes N2 Metastases in 4 to 9 axillary lymph nodes
N3 Metastases in 10 or more axillary lymph nodes
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-N0
4.048800E-01
Normal-vs-N1
2.832200E-01
N0-vs-N1
4.864400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Whole exome sequencing data is not available for 3 samples.
TP53 mutation status is obtained from TCGA whole exome sequencing data. We downloaded Mutation Annotation Format (MAF) files (derived from VarScan2) from Genomic Data Commons portal. The sample with/without TP53 mutation were matched with RNA-seq data
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-TP53-Mutant
4.178400E-04
Normal-vs-TP53-NonMutant
9.478400E-01
TP53-Mutant-vs-TP53-NonMutant
7.54000195613003E-11
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
